Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 117Gynecologic 4CNS 4Sarcoma 2Genitourinary 2Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 38Docetaxel 23Paclitaxel 20Trastuzumab 19Cyclophosphamide 18Gemcitabine 17Carboplatin 17Magnetic Resonance Spectroscopy 16Radiotherapy 14Nivolumab 13Radiosurgery 12Surveys and Questionnaires 11Specimen Handling 10Fulvestrant 10fludarabine 9aldesleukin 9Vinorelbine 9Blood Specimen Collection 9Taxes 8Injections 8Drug Therapy 8Cisplatin 8Capecitabine 8Bevacizumab 8Standard of Care 7Psychiatric Rehabilitation 7Fluorodeoxyglucose F18 7Early Intervention, Educational 7sargramostim 6palbociclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × eribulin × Thoracic × Clear all
NCT02014337 2018-01-17

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

Phase 1 Completed
37 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡